Immune-microbiome interplay and its implications in neurodegenerative disorders

Uniyal, Ankit; Tiwari, Vinod; Rani, Mousmi

doi:10.1007/s11011-021-00807-3

Cited by 7 publications

(3 citation statements)

References 205 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, commensal bacteria such as Escherichia (Lee et al, 2020), Streptococcus (Macrì et al, 2018) and Enterococcus may contribute to the regulation of dopamine levels, while Bifidobacterium and Lactobacillus can produce gammaaminobutyric acid, which is also involved in dendritic and T cell differentiation (Powell et al, 2017). The inflammatory component associated with neurodegeneration and the contribution of GM in the regulation of neurotransmission make it plausible to associate psychiatric or neurodegenerative disorders such as Alzheimer Disease (AD), Parkinson Diseases (PD), Multiple Sclerosis (MS), Amyotrophic lateral sclerosis (ALS) and Huntington's disease with GM alterations (Uniyal et al, 2021). Interestingly, epidemiological data suggest that diet could play a preventive or delaying role in prion and prion-like neurodegenerative diseases, and diet is a major driver of GM variation (Toni et al, 2017).…”

Section: Dysbiosis and Neurodegenerationmentioning

confidence: 99%

“…These modifications also correlate with alterations in the microbial metabolism of tryptophan and betaglucuronides (Bedarf et al, 2017), involved in neurotransmitter biosynthesis. In addition to this, GM dysbiosis could be involved in PD development by enhancing alpha-synuclein aggregation in the intestinal submucosa neurons, which may propagate to the CNS via the vagal nerve route (Fang et al, 2020;Uniyal et al, 2021).…”

Section: Dysbiosis and Neurodegenerationmentioning

confidence: 99%

See 1 more Smart Citation

Nutraceuticals in the Modulation of the Intestinal Microbiota: Current Status and Future Directions

Spisni

Turroni

Alvisi³

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Pharmaceutical interest in the human intestinal microbiota has increased considerably, because of the increasing number of studies linking the human intestinal microbial ecology to an increasing number of non-communicable diseases. Many efforts at modulating the gut microbiota have been made using probiotics, prebiotics and recently postbiotics. However, there are other, still little-explored opportunities from a pharmaceutical point of view, which appear promising to obtain modifications of the microbiota structure and functions. This review summarizes all in vitro, in vivo and clinical studies demonstrating the possibility to positively modulate the intestinal microbiota by using probiotics, prebiotics, postbiotics, essential oils, fungus and officinal plants. For the future, clinical studies investigating the ability to impact the intestinal microbiota especially by using fungus, officinal and aromatic plants or their extracts are required. This knowledge could lead to effective microbiome modulations that might support the pharmacological therapy of most non-communicable diseases in a near future.

show abstract

Section: Dysbiosis and Neurodegenerationmentioning

confidence: 99%

Section: Dysbiosis and Neurodegenerationmentioning

confidence: 99%

Nutraceuticals in the Modulation of the Intestinal Microbiota: Current Status and Future Directions

Spisni

Turroni

Alvisi³

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…For example, the immune system is modulated by microbiomes, state of mental health, biometal levels, diet, sleep, environmental pollution, infections, etc. [9] [10]. And conversely, many of these factors can also potentially be affected by the immune system.…”

Section: Rethinking Our Approach To Alzheimer's Diseasementioning

confidence: 99%

We Should Apply a “One Health” Approach to Understand and Treat Alzheimer’s Disease

White¹

2021

AAD

View full text Add to dashboard Cite

Despite many decades of researches and large numbers of clinical trials, there remain no effective treatments for Alzheimer's disease, a major degenerative ageing brain disorder. The potential treatments have focused on targeting the accumulation of amyloid beta-peptide in the brains of patients, but without success in slowing the disease. Many studies have now identified a large range of pathological changes (i.e. altered immune activity, mitochondrial impairment, abnormal microbiome), and links to the external environment (i.e. associations with infections, the influence of air pollution). While the concept of One Health (which considers links between the environment and human disease) has traditionally been applied to the understanding of the human infectious disease, it is argued here that the One Health approach should be adopted for Alzheimer's disease. This would provide a far more holistic understanding of the disease, and its relationship to a growing number of exogenous factors, as well as could potentially lead to new treatment options targeted at the confluence of external influences, and internal molecular pathways.

show abstract

Utility of zebrafish-based models in understanding molecular mechanisms of neurotoxicity mediated by the gut–brain axis

Adedara,

Mohammed,

Canzian

et al. 2024

Advances in Neurotoxicology

View full text Add to dashboard Cite

Immune-microbiome interplay and its implications in neurodegenerative disorders

Cited by 7 publications

References 205 publications

Nutraceuticals in the Modulation of the Intestinal Microbiota: Current Status and Future Directions

Nutraceuticals in the Modulation of the Intestinal Microbiota: Current Status and Future Directions

We Should Apply a “One Health” Approach to Understand and Treat Alzheimer’s Disease

Utility of zebrafish-based models in understanding molecular mechanisms of neurotoxicity mediated by the gut–brain axis

Contact Info

Product

Resources

About